TESARO (TSRO) Posts Smaller Q2 Loss on Higher Revs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Tesaro Announces Second-Quarter 2016 Operating Results
August 4, 2016 4:06 PM EDTPositive Phase 3 data reported by TESARO and ENGOT from the NOVA trial of niraparib in a broad population of patients with platinum-sensitive, recurrent ovarian cancerPre-launch planning underway to support four potential product launches in 2017 across U.S. and EuropeExpansion of TESARO European commercial organization now ongoing  Immuno-oncology programs continue to advance, with candidates targeting TIM-3 and PD-1 now in Phase 1 clinical trials; combination trials targeted for 2017Cash and cash equivalents totaled approximately $320 million as of June 30, 2016; additional $409 million raised in a follow-on offering completed in... More
